Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism.
Human deoxyribonuclease I (DNase I), an enzyme used to treat cystic fibrosis patients, has been engineered to more effectively degrade double-stranded DNA to lower molecular weight fragments by altering its functional mechanism from the native single-stranded nicking pathway to a much more efficient one which results in increased double-stranded scission. By introducing positively charged amino acids at DNase I positions that can interact favorably with the proximal negatively charged phosphate groups of the DNA, we have created a hyperactive variant with approximately 35-fold higher DNA-degrading activity relative to wild type. This enhancement can be attributed to both a decrease in Km and an increase in Vmax. Furthermore, unlike wild-type DNase I, the hyperactive variants are no longer inhibited by physiological saline. Replacement of the same positions with negatively charged amino acids greatly reduced DNA cleavage activity, consistent with a repulsive effect with the neighboring DNA phosphates. In addition, these variants displayed similar activities toward a small synthetic substrate, p-nitrophenyl phenylphosphonate, suggesting that the difference in DNA cleavage activity is due to the interaction of the engineered charged residues with the DNA phosphate backbone rather than any change in catalytic machinery. Finally, experiments involving the repair of DNase I digested DNA with T4 DNA ligase and the Klenow fragment of DNA polymerase I suggest that single-stranded gaps are introduced by the hyperactive variants. Thus, the increased functional activity of the hyperactive variants may be explained in part by a shift toward a processive DNA nicking mechanism, which leads to a higher frequency of double-stranded breaks.
Pan
C Q
CQ
Department of Protein Engineering, Genentech, Inc., South San Francisco, California 94080, USA.
Lazarus
R A
RA
D002118:Calcium / Q000494:pharmacology; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D011088:DNA Ligases / Q000378:metabolism; D004256:DNA Polymerase I / Q000378:metabolism; D004260:DNA Repair; D004278:DNA, Superhelical / Q000378:metabolism; D003850:Deoxyribonuclease I / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D008274:Magnesium / Q000494:pharmacology; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D010957:Plasmids; D015202:Protein Engineering / Q000379:methods*; D012965:Sodium Chloride / Q000494:pharmacology; D013329:Structure-Activity Relationship
D004278:DNA, Superhelical; D012965:Sodium Chloride; D004247:DNA; D004256:DNA Polymerase I; D003850:Deoxyribonuclease I; D011088:DNA Ligases; D008274:Magnesium; D002118:Calcium